J2H-2002

J2H-2002 is a targeted protein degradation (TPD) drug candidate developed by J2H Biotech for the treatment of non-small cell lung cancer (NSCLC). It functions as a proteolysis-targeting chimera (PROTAC), specifically designed to degrade mutant forms of the epidermal growth factor receptor (EGFR), including the EGFR C797S mutation, which is associated with resistance to existing EGFR inhibitors. Preclinical studies have demonstrated that J2H-2002 can inhibit cancer growth by up to 95% in animal models with triple-mutant lung cancer, without notable side effects such as weight loss. The drug is currently in the discovery stage and has not yet entered clinical trials[1][3][4][5].